MindMed Publishes Report by Leading FDA Experts Validating MindMed's MM-120 Drug Development Strategy

Independent Third-Party Firm, Led by Former Senior FDA Officials, Calls Phase 2b Trial “Well-designed” and “Essential”


Report Further Demonstrates that FCM’s Proposal... | May 25, 2023

Related Keywords

Chad ,Canada ,New York ,United States ,Canadian ,Scott Freeman ,John Jenkins ,Robert Barrow ,Sandy Kweder ,Jake Freeman ,Nasdaq ,Morrow Sodali ,Company Board ,Drug Administration ,Company Annual Report On Form ,Company Quarterly Report On Form ,Fcm Mm Holdings ,Greenleaf Health Inc ,Exchange Commission ,Medicine Mindmed Inc ,Office Of New Drugs ,Company Or Mindmed ,Mind Medicine ,Greenleaf Health ,Deputy Director ,New Drugs ,Drug Evaluation ,Chad Boulanger ,General Meeting ,Chief Executive Officer ,Brokers Call ,Call Toll Free ,Annual Report ,Quarterly Report ,Note Regarding Forward Looking Statements ,Financial Condition ,Annual Meeting ,Electronic Disclosure ,Mind Medicine Mindmed Stock Exchange ,News ,Information ,Press Release ,Independent ,Bed ,Y ,Former ,Senior ,Fda ,Calls ,Hase ,Tb ,Trial ,End ,Urther ,Emonstrates ,Hat Mnmd Ca60255c8850 ,